Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
This trial is active, not recruiting.
|Condition||mitral valve regurgitation|
|Start date||November 2012|
|End date||January 2017|
|Trial size||50 participants|
|Trial identifier||NCT01740583, CLPR-007|
The purpose of this study is to test the safety and device performance of the Mitralign system ("MPAS") to treat functional mitral valve regurgitation.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Medellin, Colombia||Clinica CardioVID||no longer recruiting|
|Valle del Cauca, Colombia||Antonio Dager, MD||no longer recruiting|
|Bordeaux-Pessac, France||Bordeaux Heart University Hospital||no longer recruiting|
|Toulouse, France||Clinique Pasteur||no longer recruiting|
|Asuncion, Paraguay||Sanatorio Italiano||no longer recruiting|
|Bielsko-Biala, Poland||American Heart of Poland S.A.||no longer recruiting|
|Poznan, Poland||Centrum Medyczne HZP||no longer recruiting|
|Warsaw, Poland||Instytutem Kardiologii||no longer recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
Major Adverse Events (MAE)
time frame: within 30 days post procedure
time frame: at 6 months
Male or female participants at least 18 years old.
Inclusion Criteria: - NYHA II-IV - Structurally normal mitral valve - At least Grade 2 mitral regurgitation - Left ventricular ejection fraction not less than 20% and not greater than 45% - Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5 cm Exclusion Criteria: - Pregnant or lactating female - Mitral stenosis - Mod/severe aortic stenosis or regurgitation - Mod/severe tricuspid stenosis or regurgitation - Endocarditis - Previous mitral valve repair or MV replacement - Bioprosthetic or mechanical aortic valve - Known unstable angina or MI within 30 days prior to procedure - CVA within past 6 months - Known contraindications to blood transfusion, contrast dye, DAPT
|Official title||A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation|
|Principal investigator||Adrian Ebner, M.D.|
|Description||The ALIGN study is a single arm, prospective study. The objective of the study is to investigate the safety and performance of a catheter-based plication device intended to reduce the circumference of the dilated mitral valve. The study will enroll up to 50 subjects from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who will be followed for 36 months post index procedure. Enrollment is defined at the time the study device is inserted into the body and patients will be followed at 30 days, and Months 6, 12, 24 and 36 post index procedure.|
Call for more information